Data supports booster dose of Johnson & Johnson vaccine

21 September, 2021

21 September: Johnson & Johnson have published additional data showing that protection against COVID-19 increases when a booster shot of the Johnson & Johnson vaccine is administered. The Phase 3 ENSEMBLE 2 study showed that a second dose of the Johnson & Johnson COVID-19 vaccine given 56 days after the first dose provided increased protection against severe illness and symptomatic illness. The study also demonstrated antibody levels higher than observed after the single dose.

The company will be applying for approval of a booster dose from the United States Food and Drug Administration (FDA) and other regulatory bodies.

25 August 2021: According to the manufacturer’s press release, ongoing study of the response to the Johnson & Johnson vaccine has shown evidence to support a booster dose. Data published in July in The New England Journal of Medicine, found neutralizing antibodies in those who had received a single dose up to eight months later. The interim data studying the efficacy of booster doses, which has not been peer reviewed, found that a booster dose increased neutralising titres by nearly three times.

Dr. Mathai Mammen had this statement: “We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine. We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination.”

LATEST NEWS

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. …
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. …